Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John H. McDonald is active.

Publication


Featured researches published by John H. McDonald.


Current Oncology Reports | 2002

Protein kinase C inhibitors

William F. Heath; Michael R. Jirousek; John H. McDonald; Christopher John Rito

Protein kinase C (PKC) is a family of serine-threonine protein kinases that are involved in signal transduction pathways that regulate growth factor response, proliferation, and apoptosis. Its central role in these processes, which are closely involved in tumor initiation, progression, and response to antitumor agents, makes it an attractive therapeutic target in cancer. Despite initial activity seen in melanoma (bryostatin and UCN-01), non-Hodgkin’s lymphoma (ISIS 3521, bryostatin, and UCN-01), and ovarian carcinoma (ISIS 3521 and bryostatin) in phase I studies, single-agent activity in those phase II studies reported to date has been limited. Preclinical data highlight a role for PKC in modulation of drug resistance and synergy with conventional cytotoxic drugs. A randomized phase III study of ISIS 3521 in combination with carboplatin and paclitaxel, compared with chemotherapy alone, in advanced non-small-cell lung cancer is underway. This paper reviews the rationale for using PKC inhibitors in cancer therapy, the challenges for clinical trial design, and the recent clinical experience with modulators of PKC activity.


Bioorganic & Medicinal Chemistry Letters | 1998

Synthesis of bisindolylmaleimides using a palladium catalyzed cross-coupling reaction

David Andrew Neel; Michael R. Jirousek; John H. McDonald

Bisindolylmaleimides are known to be potent and selective PKC inhibitors. A new synthesis of this class of compound is reported. The key step is a Suzuki cross-coupling reaction using a readily available indolylmaleimide triflate intermediate.


Molecular Diversity | 1997

The use of high-throughput synthesis and purification in the preparation of a directed library of adrenergic agents

Miles Goodman Siegel; Athony J. Shuker; Christine Ann Droste; Patrick J. Hahn; Cynthia Darshini Jesudason; John H. McDonald; Donald P. Matthews; Christopher John Rito; Andrew John Thorpe

A library of potential agonists and antagonists for adrenergic receptors was prepared using high-throughput solution-phase parallel synthesis. Traditional solution-phase reductive amination reactions followed by rapid purification by ion exchange chromatography yielded products with near-analytical purity. An array of ketones and amines, arranged in an 8 × 12 matrix, were combined to form 96 individual compounds.


Bioorganic & Medicinal Chemistry Letters | 1995

Synthesis of bisindolylmaleimide macrocycles

Michael R. Jirousek; James Ronald Gillig; David Andrew Neel; Christopher John Rito; Douglas D. O'Bannon; William F. Heath; John H. McDonald; Margaret M. Faul; Leonard L. Winneroski; Anita Melikian-Badalian; Matthew Baevsky; Larwence M Ballas; Steven E. Hall

Abstract The synthesis of a novel class of N-N′-macrocyclic bisindolylmaleimides is reported. The key step involves a remarkably efficient intramolecular cyclization reaction. The method was further developed to provide an efficient synthesis of this type of macrocycle through an intermolecular alkylation with subsequent intramolecular cyclization.


Bioorganic & Medicinal Chemistry Letters | 1998

3-Trifluoromethylcarbacephems: Synthesis of broad spectrum antibacterial compounds

Gwendolyn Kay Cook; William Joseph Hornback; John H. McDonald; John E. Munroe; Nancy June Snyder

The enhanced stability of the carbacephem nucleus over the corresponding cephalosporin nucleus has allowed the synthesis of 7-arylglycyl-3-trifluoromethyl-carbacephems. These unique carbacephems possess broad spectrum activity and high stability to both plasmid and chromosomally mediated beta-lactamases.


Journal of Medicinal Chemistry | 1996

(S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.

Michael R. Jirousek; James Ronald Gillig; Cecile M. Gonzalez; William F. Heath; John H. McDonald; David Andrew Neel; Christopher John Rito; Upinder Singh; Lawrence E. Stramm; Anita Melikian-Badalian; Matthew Baevsky; Lawrence M. Ballas; Leonard L. Winneroski; Margaret M. Faul


Archive | 1996

Selective beta3 adrenergic agonists

Cynthia Darshini Jesudason; Donald P. Matthews; John H. McDonald; David Andrew Neel; Christopher John Rito; Anthony J. Shuker; Michael Gregory Bell; Thomas Alan Crowell; Christine Ann Droste; Mark Alan Winter


Journal of Medicinal Chemistry | 1990

Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins.

Larry C. Blaszczak; Raymond F. Brown; Gwendolyn Kay Cook; William Joseph Hornback; Joseph M. Indelicato; Chris L. Jordan; Alan S. Katner; Michael Dean Kinnick; John H. McDonald


Journal of Organic Chemistry | 1989

Palladium-catalyzed chemistry of .beta.-lactam vinyl triflates: coupling with organostannanes and alkoxycarbonylation

Gwendolyn Kay Cook; William Joseph Hornback; Chris L. Jordan; John H. McDonald; John E. Munroe


Journal of Medicinal Chemistry | 1989

3-Sulfonyl-1-carba-1-dethiacephems.

Thomas Alan Crowell; Basil D. Halliday; John H. McDonald; Joseph M. Indelicato; Carol Elaine Pasini; Ernie C. Y. Wu

Collaboration


Dive into the John H. McDonald's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge